2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Blood Banking, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Vaccines, Non-Biological Therapies, Opioids, Women’s Health, Adverse Events, Biological Processes, Hematopoiesis, Metabolism, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Immunology, Immunodeficiency, Infectious Diseases, Bacterial, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

4683 Comparative inpatient analgesia for uncomplicated vaso-occlusive episodes: Divergent practice at adjacent pediatric and adult hospitals

Anshul Raman, MD, Allie Wallace, DO2, Aishani Vengala3, Nivedita Jayasekar4, An-Lin Cheng, PhD5, Shabnam Arsiwala6, Anuj Shrestha, MD, FACP7
1 Children's Mercy Kansas City, Kansas City, Missouri, United States, University of Missouri-Kansas City, Kansas City, Missouri, United States
2 Children's Mercy Kansas City, Kansas City, Missouri, United States
3 University of Missouri-Kansas City, Kansas City, Missouri, United States
4 University of Missouri-Kansas City, Kansas City, Missouri, United States
5 University of Missouri-Kansas City, Kansas City, Missouri, United States
6 Children's Mercy Kansas City, Kansas City, Missouri, United States
7 University of Missouri-Kansas City, Kansas City, Missouri, United States

Objective: To determine and compare the differences in pain management strategies at an adjacent pediatric vs adult hospital for patients admitted with uncomplicated sickle cell vaso-occlusive episodes (VOEs). 

Methods: This was a retrospective study reviewing patients admitted for uncomplicated sickle cell VOEs at Children's Mercy Hospital (CMH) vs University Health (UH) in the year 2024. Details of pain management strategies were recorded and compared, primarily including opioid medications, routes, and doses [which were standardized into morphine milliequivalents (MMEs)], as well as non-opioid medications. MMEs were further calculated based on route and then averaged per day of admission as well as per kg body weight of patient 

Results: This study reviewed a total of 260 admissions – 144 pediatric admissions at CMH (ages 1-20), and 116 adult admissions at University Health (ages 18-62).  

MMEs: Pediatric patients at CMH on average received 122% more MMEs per day of admission - 226.88 compared to adult patients at UH on average receiving 186.3 MMEs per day of admission (p=0.0046). This difference became more pronounced when adjusting for body weight – CMH patients received 1.5 times as much opioids by dose – 4.2 MMEs per kg body weight per day of admission (MME/kg/day) compared to UH patients receiving 2.8 MMEs/kg/day (p < 0.0001).  

Route: At CMH, PCAs were utilized in 97.9% of admissions compared to at UH where it was utilized in 3.4% of admissions. At CMH, of the total opioid MMEs given, 3.6% were PO, 3.2% were IV or intranasal, and 93.2% were via PCA. In comparison, at UH, of the total opioid MMEs, 45.4% were PO, 53.3% were IV or intranasal, and 1.3% were via PCA. Intranasal fentanyl and PO methadone were only utilized at CMH. PO morphine and PO buprenorphine were only utilized at UH. 

Adjuncts: There was no statistically significant difference in the number of non-opioid adjuncts used for any given admission (p=0.132), but there were some statistically significant differences in which specific medications were used. At CMH, acetaminophen was used with 100% of admissions, ibuprofen with 70.1%, celecoxib with 11.1%, ketorolac with 71.5%, and muscle relaxants with 19.4%. This is in comparison to UH where acetaminophen was used with 88.8% of admissions, ibuprofen with 36.2%, celecoxib with 0.9%, ketorolac with 59.5%, and muscle relaxants with 37% (p < 0.0001). There were similar rates of use of topical medications (such as lidocaine patches and gel) and medications targeting neuropathic pian. Ketamine and Dexmedetomidine were utilized only at CMH. 

Length of Stay (LOS): There was no significant difference in the length of stay (p=0.255). Median LOS at both institutions was 4 days. 

Conclusion: At our adjacent pediatric and adult hospitals, pediatric patients received a significantly higher amount of opioid medications. More research needs to be done to understand the underlying reasons for these differences, whether this is representative of under-treatment of adult patients or over-treatment of pediatric patients. Possible considerations for these differences in our institution include: CMH admits sickle cell VOE patients to a Hematology team compared to UH which admits to Medicine teams which may leave differing levels of comfort in managing VOEs, general opioid prescribing reluctance that is more prevalent in adult care compared to pediatric care, and bias and stigma more prevalent in adult care compared to more advocacy for optimal pain control for children. The length of stay did not differ between the two hospitals for VOE indicating there may be higher opioid tolerance in pediatric population whereas there may be a higher pain tolerance and increased chronic pain in the adult population. 

Anshul Raman, MD: No relevant conflicts of interest to declare.